Matthias Eyrich

Prof. Dr. Matthias Eyrich

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
HSHila Shaim
Hila Shaim
MSMayra Shanley
Mayra Shanley
RBRafet Basar
Rafet Basar
MDMay Daher
May Daher
JGJoy Gumin
Joy Gumin
KRKatayoun Rezvani
Katayoun Rezvani
Glioblastoma multiforme (GBM), the most aggressive brain cancer, recurs because glioblastoma stem cells (GSCs) are resistant to all standard therapies. We showed that GSCs, but not normal astrocytes, are sensitive to lysis by healthy allogeneic natural killer (NK) cells in vitro. Mass cytometry and single-cell RNA sequencing of primary tumor samples revealed that GBM tumor–infiltrating NK cells acquired an altered phenotype associated with impaired lytic function relative to matched peripheral blood NK cells from patients with GBM or healthy donors. We attributed this immune evasion tactic to direct cell-to-cell contact between GSCs and NK cells via αv integrin–mediated TGF-β activation. Treatment of GSC-engrafted mice with allogeneic NK cells in combination with inhibitors of integrin or TGF-β signaling or with TGFBR2 gene–edited allogeneic NK cells prevented GSC-induced NK cell dysfunction and tumor growth. These findings reveal an important mechanism of NK cell immune evasion by GSCs and suggest the αv integrin/TGF-β axis as a potentially useful therapeutic target in GBM.

1 March 2003 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
PLP Ljungman
P Ljungman
PRP Ribaud
P Ribaud
MEMatthias Eyrich
Matthias Eyrich
SMS Matthes-Martin
S Matthes-Martin
HEH Einsele
H Einsele
CCC Cordonnier
C Cordonnier
Adenovirus is an important cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation and there is no established therapy. Cidofovir has in vitro efficacy against adenovirus. We performed a retrospective analysis of 45 patients treated with cidofovir for adenovirus from 10 centers. In total, 16 patients had definite adenovirus disease, 13 probable disease, and 16 asymptomatic infections. A total of 31 (69%) patients were successfully treated with cidofovir, 10 failed, and four were not evaluable owing to early death from other causes. Cidofovir therapy was successful in 10 patients with adenovirus disease, 10 patients with probable disease, and in 10 patients with asymptomatic infections. The overall survival at 28 days and 6 months after initiation of cidofovir therapy was 76 and 46%, respectively. Of the patients, 18 developed toxicity associated with cidofovir: 14 developed renal toxicity and four other types of toxicities. We conclude that cidofovir may be useful against adenovirus after allogeneic hematopoietic stem cell transplantation but additional studies are needed.

1 September 2009 in The Lancet
Verified
Journal Article
Closed access
KSKarin C Straathof
Karin C Straathof
KRKanchan Rao
Kanchan Rao
MEMatthias Eyrich
Matthias Eyrich
GHGeoff Hale
Geoff Hale
PBPrudence Bird
Prudence Bird
PAPersis Jal Amrolia
Persis Jal Amrolia

7 June 2017 in Blood Advances
Verified
Journal Article
Open access
PDF file
EREliana Ribechini
Eliana Ribechini
JHJames A. Hutchinson
James A. Hutchinson
SHSabine Hergovits
Sabine Hergovits
MHMarion Heuer
Marion Heuer
JLJörg Lucas
Jörg Lucas
MLManfred B Lutz
Manfred B Lutz
Key Points: Novel GM-CSF signaling pathways through IFN-γR/IRF-1 and AKT/mTOR provide monocyte licensing for suppressor function. Only licensed but not fresh Ly-6Chigh murine or human CD14+ monocytes secrete nitric oxide or IDO for T-cell suppression.

22 October 2008 in Cytometry Part A
Verified
Journal Article
Open access
PDF file
MWMatthias Wölfl
Matthias Wölfl
JKJürgen Kuball
Jürgen Kuball
MEMatthias Eyrich
Matthias Eyrich
PSPaul G. Schlegel
Paul G. Schlegel
PGPhilip D. Greenberg
Philip D. Greenberg
CD137 (4‐1BB) is a member of the TNFR‐family with costimulatory function, triggering prosurvival signals in activated T‐cells. Upregulation of CD137 upon stimulation allows identifying and isolating live, human antigen‐specific CD8+ T‐cells of all phenotypes, and therefore provides a comprehensive detection method. Furthermore responses against antigen mixtures can be easily detected, enabling antigen discovery in a stepwise deconvoluting approach. In this article, we will discuss various aspects of this methodology, including potential pitfalls as well as a variety of applications, as illustrated by examples from our laboratory. © 2008 International Society for Advancement of Cytometry

3 June 2003 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
MTMaren Tomaske
Maren Tomaske
ABAxel Bosk
Axel Bosk
MEMatthias Eyrich
Matthias Eyrich
PBPeter Bader
Peter Bader
DNDietrich Niethammer
Dietrich Niethammer
Summary. The risk of mortality in children admitted to the paediatric intensive care unit (PICU) after haematopoietic stem cell transplantation is felt to be very high. Life‐threatening complications leading to PICU admission are due to organ toxicity caused by conditioning regimes and graft‐versus‐host disease (GVHD), systemic infections and other organ dysfunctions. Data collected between October 1998 and December 2001 of paediatric patients undergoing haematopoietic stem cell transplantation and thereafter admitted to the PICU were retrospectively analysed in order to reveal the possible causes and risk factors related to death while in the PICU. Twenty‐six PICU admissions were recorded. We found a mortality rate of 57·7% and a 6‐month survival rate of 23·1%. Univariate analysis identified an oncological paediatric risk of mortality (O‐PRISM) score above 10 points, sustained renal failure and a failed negative fluid balance as significant predictors to non‐survival.